Repligen | RGEN - Equity Capital And Reserves



Repligen reported $1.99B in Equity Capital and Reserves for its fiscal quarter ending in March of 2025.


Equity Capital And Reserves Change Date
Agilent USD 6.37B 234M Jul/2025
Align Technology USD 3.79B 57.74M Mar/2025
Bio Techne USD 1.92B 99.22M Jun/2025
BioMarin Pharmaceutical USD 6.03B 233.65M Jun/2025
Bristol-Myers Squibb USD 17.49B 100M Jun/2025
Bruker USD 1.87B 33.9M Jun/2025
Charles River Laboratories USD 3.31B 119.03M Jun/2025
Danaher USD 52.33B 1.48B Jun/2025
Dentsply International USD 1.96B 50M Jun/2025
Exact Sciences USD 2.47B 72.51M Jun/2025
General Electric Aerospace USD 19.14B 116M Jun/2025
Henry Schein USD 3.44B 135M Jun/2025
Illumina USD 2.26B 110M Jun/2025
IQVIA Holdings USD 5.78B 199M Jun/2025
Mettler Toledo International USD -258793000 76.81M Jun/2025
Myriad Genetics USD 704.9M 3.8M Mar/2025
Pfizer USD 88.7B 1.64B Jun/2025
Repligen USD 1.99B 12.76M Mar/2025
Revvity USD 7.64B 29.74M Mar/2025
Standard Biotools USD 424.54M 47.18M Jun/2025
Thermo Fisher Scientific USD 49.36B 227M Mar/2025
Waters USD 2.16B 197.42M Jun/2025
West Pharmaceutical Services USD 2.93B 246M Jun/2025